GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway

Biochemical and Biophysical Research Communications

Volumn 476, Issue 4, 2016, Pages 196-203

  He, Qin ^a   Sha, Sha ^a   Sun, Lei ^a   Zhang, Jing ^a   Dong, Ming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

AMPK; Autophagy; Hepatocyte steatosis; Liraglutide; mTOR

Indexed keywords

BAFILOMYCIN A1; BECLIN 1; CHLOROQUINE; CHOLESTEROL; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPID; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN LC3B; PROTEIN P62; PROTEIN SQSTM1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG MECHANISM; FATTY LIVER; FLUORESCENCE MICROSCOPY; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIPID LIVER LEVEL; LIPID STORAGE; LIVER CELL; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSMISSION ELECTRON MICROSCOPY; WEIGHT REDUCTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CELL LINE; DRUG EFFECTS; LIPID METABOLISM; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PATHOLOGY; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AUTOPHAGY; CELL LINE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIPIDS; LIRAGLUTIDE; LIVER; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84973561960     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.05.086     Document Type: Article

References (29)

1. [1] Amarapurkar, D.N., Hashimoto, E., Lesmana, L.A., Sollano, J.D., Chen, P.J., Goh, K.L., How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. J. Gastroenterol. Hepatol. 22 (2007), 788–793.
2. [2] Ferre, P., Foufelle, F., Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 12 (2010), 83–92, 10.1111/j.1463-1326.2010.01275.x.
3. [3] Rask, E., Olsson, T., Soderberg, S., Johnson, O., Seckl, J., Holst, J.J., Ahren, B., Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24 (2001), 1640–1645.
4. [4] Gupta, N.A., Mells, J., Dunham, R.M., Grakoui, A., Handy, J., Saxena, N.K., Anania, F.A., Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51 (2010), 1584–1592, 10.1002/hep.23569.
5. [5] Rossi, M.C., Nicolucci, A., Liraglutide in type 2 diabetes: from pharmacological development to clinical practice. Acta Biomed. 80 (2009), 93–101.
6. [6] Wajcberg, E., Amarah, A., Liraglutide in the management of type 2 diabetes. Drug Des. Devel. Ther. 4 (2010), 279–290, 10.2147/DDDT.S10180.
7. [7] Amir, M., Czaja, M.J., Autophagy in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5 (2011), 159–166, 10.1586/egh.1511.1584.
8. [8] Park, H.W., Lee, J.H., Calcium channel blockers as potential therapeutics for obesity-associated autophagy defects and fatty liver pathologies. Autophagy 10 (2014), 2385–2386, 10.4161/15548627.15542014.15984268.
9. [9] Yang, Z., Klionsky, D.J., An overview of the molecular mechanism of autophagy. Curr. Top. Microbiol. Immunol. 335 (2009), 1–32, 10.1007/1978-1003-1642-00302-00308_00301.
10. [10] Xu, G., Hong, X., Tang, H., Jiang, S., Liu, F., Shen, Z., Li, Z., Zhang, W., Ghrelin regulates GLP-1 production through mTOR signaling in L cells. Mol. Cell Endocrinol. 416 (2015), 9–18, 10.1016/j.mce.2015.1008.1016 Epub 2015 Aug 1013.
11. [11] Xu, G., Li, Z., Ding, L., Tang, H., Guo, S., Liang, H., Wang, H., Zhang, W., Intestinal mTOR regulates GLP-1 production in mouse L cells. Diabetologia 58 (2015), 1887–1897, 10.1007/s00125-00015-03632-00126 Epub 02015 Jun 00123.
12. [12] Gomez-Lechon, M.J., Donato, M.T., Martinez-Romero, A., Jimenez, N., Castell, J.V., O'Connor, J.E., A human hepatocellular in vitro model to investigate steatosis. Chem. Biol. Interact. 165 (2007), 106–116 Epub 2006 Nov 2023.
13. [13] Cen, J., Liu, L., Li, M.S., He, L., Wang, L.J., Liu, Y.Q., Liu, M., Ji, B.S., Alteration in P-glycoprotein at the blood-brain barrier in the early period of MCAO in rats. J. Pharm. Pharmacol. 65 (2013), 665–672, 10.1111/jphp.12033 Epub 12013 Feb 12026.
14. [14] Xu, F., Burk, D., Gao, Z., Yin, J., Zhang, X., Weng, J., Ye, J., Angiogenic deficiency and adipose tissue dysfunction are associated with macrophage malfunction in SIRT1-/– mice. Endocrinology 153 (2012), 1706–1716, 10.1210/en.2011-1667 Epub 2012 Feb 1707.
15. [15] Noureddin, M., Yates, K.P., Vaughn, I.A., Neuschwander-Tetri, B.A., Sanyal, A.J., McCullough, A., Merriman, R., Hameed, B., Doo, E., Kleiner, D.E., Behling, C., Loomba, R., Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58 (2013), 1644–1654, 10.1002/hep.26465 Epub 22013 Oct 26462.
16. [16] Cuthbertson, D.J., Irwin, A., Gardner, C.J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E.L., Adams, V.L., Pushpakom, S.P., Pirmohamed, M., Kemp, G.J., Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One, 7, 2012, e50117, 10.51371/journal.pone.0050117 Epub 0052012 Dec 0050116.
17. [17] Wang, Y., Parlevliet, E.T., Geerling, J.J., van der Tuin, S.J., Zhang, H., Bieghs, V., Jawad, A.H., Shiri-Sverdlov, R., Bot, I., de Jager, S.C., Havekes, L.M., Romijn, J.A., Willems van Dijk, K., Rensen, P.C., Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br. J. Pharmacol. 171 (2014), 723–734, 10.1111/bph.12490.
18. [18] Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., Weng, J., SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes 63 (2014), 3637–3646, 10.2337/db3614-0263 Epub 2014 Jun 3619.
19. [19] Jung, T.W., Hong, H.C., Hwang, H.J., Yoo, H.J., Baik, S.H., Choi, K.M., C1q/TNF-Related Protein 9 (CTRP9) attenuates hepatic steatosis via the autophagy-mediated inhibition of endoplasmic reticulum stress. Mol. Cell Endocrinol. 417 (2015), 131–140, 10.1016/j.mce.2015.1009.1027 Epub 2015 Sep. 1028.
20. [20] Sun, L., Zhang, S., Yu, C., Pan, Z., Liu, Y., Zhao, J., Wang, X., Yun, F., Zhao, H., Yan, S., Yuan, Y., Wang, D., Ding, X., Liu, G., Li, W., Zhao, X., Liu, Z., Li, Y., Hydrogen sulfide reduces serum triglyceride by activating liver autophagy via the AMPK-mTOR pathway. Am. J. Physiol. Endocrinol. Metab. 309 (2015), E925–E935, 10.1152/ajpendo.00294.02015 Epub 02015 Oct 00296.
21. [21] Yang, G., Lee, H.E., Lee, J.Y., A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Sci. Rep., 6, 2016, 24399, 10.1038/srep24399.
22. [22] Wullschleger, S., Loewith, R., Hall, M.N., TOR signaling in growth and metabolism. Cell 124 (2006), 471–484.
23. [23] Chen, Q.Y., Jiao, D.M., Wu, Y.Q., Chen, J., Wang, J., Tang, X.L., Mou, H., Hu, H.Z., Song, J., Yan, J., Wu, L.J., Chen, J., Wang, Z., MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met/PI3k/ Akt/mTOR pathway. Oncotarget, 22, 2016.
24. [24] Lakshmipathi, J., Alvarez-Perez, J.C., Rosselot, C., Casinelli, G.P., Stamateris, R.E., Rausell-Palamos, F., O'Donnell, C.P., Vasavada, R.C., Scott, D.K., Alonso, L.C., Garcia-Ocana, A., PKC-zeta is essential for pancreatic beta cell replication during insulin resistance by regulating mTOR and cyclin-D2. Diabetes, 11, 2016.
25. [25] Li, N.A., Wang, W., Xu, B., Gong, H., miR-196b regulates gastric cancer cell proliferation and invasion via PI3K/AKT/mTOR signaling pathway. Oncol. Lett. 11 (2016), 1745–1749 Epub 2016 Jan 1726.
26. [26] Wang, H., Li, X., Liu, H., Sun, L., Zhang, R., Li, L., Wangding, M., Wang, J., Six1 induces protein synthesis signaling expression in duck myoblasts mainly via up-regulation of mTOR. Genet. Mol. Biol. 39 (2016), 151–161, 10.1590/1678-4685-GMB-2015-0075.
27. [27] He, C., Klionsky, D.J., Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 43 (2009), 67–93, 10.1146/annurev-genet-102808-114910.
28. [28] Komatsu, N., Fujita, Y., Matsuda, M., Aoki, K., mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells. Oncogene 34 (2015), 5607–5616, 10.1038/onc.2015.5616 Epub 2015 Feb 5623.
29. [29] Romeo, Y., Moreau, J., Zindy, P.J., Saba-El-Leil, M., Lavoie, G., Dandachi, F., Baptissart, M., Borden, K.L., Meloche, S., Roux, P.P., RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth. Oncogene 32 (2013), 2917–2926, 10.1038/onc.2012.2312 Epub 2012 Jul 2916.